Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2026)

Royalty Pharma has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 468256000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 468256000.0, up 7.79% year-over-year; the trailing twelve-month figure through Mar 2026 was 1359015000.0 (down 23.2% YoY), and the FY2025 annual result was 1324192000.0, changed 0.5% from the prior year.
• Income from Continuing Operations came in at 468256000.0 for Q1 2026 at Royalty Pharma, up from 355913000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 806358000.0 in Q3 2024 to a low of 610030000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 351336000.0 (2023), against an average of 297318411.76.
• Across the five-year window, Income from Continuing Operations plunged 1236.61% in 2022 and soared 10266.93% in 2025, its largest moves.
• Royalty Pharma's Income from Continuing Operations stood at 610030000.0 in 2022, then jumped by 217.63% to 717586000.0 in 2023, then sank by 53.41% to 334351000.0 in 2024, then increased by 6.45% to 355913000.0 in 2025, then soared by 31.56% to 468256000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 468256000.0 (Q1 2026), 355913000.0 (Q4 2025), and 444211000.0 (Q3 2025), per Business Quant data.